NCT01136798

Impact of Exenatide on Sleep in Type 2 Diabetes

Impact of Exenatide on Sleep and Circadian Function in Type 2 Diabetes: A Pilot Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators propose a pilot study to test the novel hypothesis that Exenatide treatment in patients with type 2 diabetes results in improved sleep duration and quality and to explore the relationship between improvements in sleep and measures of metabolic and circadian function. This project would be the first to probe the relationship between incretin hormone regulation, duration and intensity of sleep, glucose tolerance and circadian dysfunction in diabetic patients.

Conditions

• Type 2 Diabetes
• Sleep Disordered Breathing

Interventions

Type	Name	Description
DRUG	Exenatide	Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
DRUG	Placebo	Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks

Timeline

• Start date: 2010-06-01
• Primary completion: 2016-09-01
• Completion: 2016-09-01
• First posted: 2010-06-03
• Last updated: 2018-09-12
• Results posted: 2018-07-31

Locations

2 sites across 1 country: United States